Impairment of lysophospholipid metabolism in obesity: Altered plasma profile and desensitization to the modulatory properties of n-3 polyunsaturated fatty acids in a randomized controlled trial

American Journal of Clinical Nutrition

Volumn 104, Issue 2, 2016, Pages 266-279

  Bas, Josep M Del ^a   Caimari, Antoni ^a   Rodriguez Naranjo, Maria Isabel ^a   Childs, Caroline E ^b   Chavez, Carolina Paras ^b   West, Annette L ^b   Miles, Elizabeth A ^b   Arola, Lluis ^a,c   Calder, Philip C ^b,d  

^a Technological Center of Nutrition and Health (CTNS)   (Spain)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Fatty liver disease; Fish oil; Inflammation; Insulin resistance; Lysophosphatidylcholine; Lysophosphatidylethanolamine; Lysophospholipid metabolism; Obesity; Omega 3; Polyunsaturated fatty acids

Indexed keywords

CARBOHYDRATE; CORN OIL; FATTY ACID; FISH OIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLETHANOLAMINE; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID; MILK FAT; OMEGA 3 FATTY ACID; PALMITIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FAT INTAKE; LYSOPHOSPHATIDIC ACID;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION PROCESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DESENSITIZATION; DIETARY INTAKE; DISEASE COURSE; FATTY LIVER; FEMALE; FOOD INTAKE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPID DIET; MALE; OBESITY; PHOSPHOLIPID BLOOD LEVEL; PHOSPHOLIPID METABOLISM; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; BLOOD; COMPLICATION; DIET THERAPY; FAT INTAKE; HEP-G2 CELL LINE; INFLAMMATION; INSULIN RESISTANCE; MIDDLE AGED; PATHOLOGY; PHARMACOLOGY;

ADULT; DIET, HIGH-FAT; DIETARY FATS; FATTY ACIDS, OMEGA-3; FATTY LIVER; FEMALE; HEP G2 CELLS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; OBESITY;

EID: 84980416719     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.116.130872     Document Type: Article

References (46)

1. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89.
2. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-80.
3. Heimerl S, Fischer M, Baessler A, Liebisch G, Sigruener A, Wallner S, Schmitz G. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS One 2014;9:e111348.
4. Barber MN, Risis S, Yang C, Meikle PJ, Staples M. Febbraio MA, Bruce CR. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 2012;7:e41456.
5. Pietilainen KH, Sysi-Aho M, Rissanen A, Seppanen-Laakso T, Yki-Jarvinen H, Kaprio J, Oresic M. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS One 2007;2:e218.
6. Graessler J, Schwudke D, Schwarz PEH, Herzog R, Shevchenko A, Bornstein SR. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 2009;4:e6261.
7. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-88.
8. Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, Lanciault C, Caprioli RM, Abumrad N, Flynn CR. Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis. PLoS One 2013;8:e57165.
9. Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012;56:118-29.
10. Lehmann R, Franken H, Dammeier S, Rosenbaum L, Kantartzis K, Peter A, Zell A, Adam P, Li J, Xu G, et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 2013;36:2331-8.
11. Bondia-Pons I, Martinez JA, de la Iglesia R, Lopez-Legarrea P, Poutanen K, Hanhineva K, Zulet M de los A. Effects of short-and longterm Mediterranean-based dietary treatment on plasma LC-QTOF/MS metabolic profiling of subjects with metabolic syndrome features: The Metabolic Syndrome Reduction in Navarra (RESMENA) randomized controlled trial. Mol Nutr Food Res 2015;59:711-28.
12. de la Iglesia R, Lopez-Legarrea P, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L, Martinez JA, Zulet MA. A new dietary strategy for long-term treatment of the metabolic syndrome is compared with the American Heart Association (AHA) guidelines: the MEtabolic Syndrome REduction in NAvarra (RESMENA) project. Br J Nutr 2014;111:643-52.
13. Grzelczyk A, Gendaszewska-Darmach E. Novel bioactive glycerolbased lysophospholipids: new data-new insight into their function. Biochimie 2013;95:667-79.
14. Li D. Omega-3 polyunsaturated fatty acids and non-communicable diseases: meta-analysis based systematic review. Asia Pac J Clin Nutr 2015;24:10-5.
15. Monteiro J, Leslie M, Moghadasian MH, Arendt BM, Allard JP, Ma DWL. The role of n-6 and n-3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct 2014;5:426-35.
16. Kim J, Li Y, Watkins BA. Fat to treat fat: Emerging relationship between dietary PUFA, endocannabinoids, and obesity. Prostaglandins Other Lipid Mediat 2013;104-105:32-41.
17. Bender N, Portmann M, Heg Z, Hofmann K, Zwahlen M, Egger M. Fish or n3-PUFA intake and body composition: a systematic review and meta-analysis. Obes Rev 2014;15:657-65.
18. Masoodi M, Kuda O, Rossmeisl M, Flachs P, Kopecky J. Lipid signaling in adipose tissue: connecting inflammation & metabolism. Biochim Biophys Acta 2015;1851:503-18.
19. Wang Y, Huang F. N-3 polyunsaturated fatty acids and inflammation in obesity: local effect and systemic benefit. BioMed Res Int 2015;2015:581469.
20. Hung ND, Sok DE, Kim MR. Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine. Inflamm Res 2012;61:473-83.
21. Hung ND, Kim MR, Sok DE. Mechanisms for anti-inflammatory effects of 1-[15(S)-hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan A-induced peritonitis. Br J Pharmacol 2011;162:1119-35.
22. Liebisch G, Schmitz G. Quantification of lysophosphatidylcholine species by high-throughput electrospray ionization tandem mass spectrometry (ESI-MS/MS). Methods Mol Biol 2009;580:29-37.
23. Rojas C, Pan-Castillo B, Valls C, Pujadas G, Garcia-Vallve S, Arola L, Mulero M. Resveratrol enhances palmitate-induced ER stress and apoptosis in cancer cells. PLoS One 2014;9:e113929.
24. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res 2015;43:W251-7.
25. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA. American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012;18:1-78.
26. Son JW, Park C, Kim S, Lee H, Lee Y, Resistance I. Changing clinical characteristics according to insulin resistance and insulin secretion in newly diagnosed type 2 diabetic patients in Korea. Diabetes Metab J 2015;39:387-94.
27. Worley B, Powers R. Multivariate analysis in metabolomics. Curr Metabolomics 2013;1:92-107.
28. Caimari A, Oliver P, Keijer J, Palou A. Peripheral blood mononuclear cells as a model to study the response of energy homeostasis-related genes to acute changes in feeding conditions. Omics 2010;14:129-41.
29. Caimari A, Oliver P, Palou A. Regulation of adiponutrin expression by feeding conditions in rats is altered in the obese state. Obesity (Silver Spring) 2007;15:591-9.
30. Sekas G, Patton GM, Lincoln EC, Robins SJ. Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J Lab Clin Med 1985;105:190-4.
31. Wallace M, Morris C, O'Grada CM, Ryan M, Dillon ET, Coleman E, Gibney ER, Gibney MJ, Roche HM, Brennan L. Relationship between the lipidome, inflammatory markers and insulin resistance. Mol Biosyst 2014;10:1586-95.
32. Rauschert S, Uhl O, Koletzko B, Kirchberg F, Mori TA, Huang R-C, Beilin LJ, Hellmuth C, Oddy WH. Lipidomics reveals associations of phospholipids with obesity and insulin resistance in young adults. J Clin Endocrinol Metab 2016;101:871-9.
33. Kim JY, Park JY, Kim OY, Ham BM, Kim H-J, Kwon DY, Jang Y, Lee JH. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J Proteome Res 2010;9:4368-75.
34. Lee SY, Kim M, Jung S, Lee S-H, Lee JH. Altered plasma lysophosphatidylcholines and amides in non-obese and non-diabetic subjects with borderline-to-moderate hypertriglyceridemia: a case-control study. PLoS One 2015;10:e0123306.
35. Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008;205:2975-84.
36. Weir JM, Wong G, Barlow CK, Greeve MA, Kowalczyk A, Almasy L, Comuzzie AG, Mahaney MC, Jowett JB, Shaw J, et al. Plasma lipid profiling in a large population-based cohort. J Lipid Res 2013;54:2898-908.
37. Sevastou I, Kaffe E, Mouratis M-A, Aidinis V. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta 2013;1831:42-60.
38. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S-19S.
39. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadl A, Zeyda M, Waldhausl W, Stulnig TM. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 2006;49:2109-19.
40. de Vries MA, Klop B, Janssen HW, Njo TL, Westerman EM, Castro Cabezas M. Postprandial inflammation: targeting glucose and lipids. Adv Exp Med Biol 2014;824:161-70.
41. Kardinaal AFM, van Erk MJ, Dutman AE, Stroeve JHM, van de Steeg E, Bijlsma S, Kooistra T, van Ommen B, Wopereis S. Quantifying phenotypic flexibility as the response to a high-fat challenge test in different states of metabolic health. FASEB J 2015;29:4600-13.
42. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-7.
43. Yea K, Kim J, Yoon JH, Kwon T, Kim JH, Lee BD, Lee H-J, Lee SJ, Kim J-I, Lee TG, et al. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J Biol Chem 2009;284:33833-40.
44. Soga T, Ohishi T, Matsui T, Saito T, MatsumotoM, Takasaki J, Matsumoto S-I, Kamohara M, Hiyama H, Yoshida S, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-proteincoupled receptor. Biochem Biophys Res Commun 2005;326:744-51.
45. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-9.
46. Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa J-P, Stojakovic T, Scharnagl H, Kofeler H, Baba HA, Gerken G, et al. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism 2014;63:1542-52.